NIH Human Microbiome Project Data as Anticipatory Prior Art
Introduction
Microbiome therapeutics, diagnostics and probiotics have attracted substantial investment and with it a growing number of patents. Typical claims cover compositions comprising specific bacterial strains or consortia, methods of treating disease by administering them, diagnostic methods that rely on microbial signatures and methods of manufacturing live biotherapeutic products. Many of these inventions were developed after a major public effort had already mapped the human microbiome: the Human Microbiome Project (HMP), funded by the U.S. National Institutes of Health (NIH). The HMP released reference genomes, 16S rRNA surveys and metagenomic data from healthy human volunteers, much of it openly accessible, beginning around 2010 and culminating in the landmark June 2012 papers in Nature.
This article examines whether and how, HMP data can be used as prior art to challenge the validity of microbiome patents. The central issue is anticipation: can a single HMP publication or dataset disclose every element of a claim, arranged as claimed, in a way that enables a skilled person to practice it? The honest answer is that HMP data will rarely anticipate a well-drafted treatment claim on its own, but it can be a powerful anticipatory reference against certain composition and diagnostic claims and a core reference in obviousness challenges. The details matter and the sections that follow explain which ones.
What the Human Microbiome Project Produced
Understanding the potential of HMP data as prior art starts with understanding what exactly was published, when and how accessibly.
| Resource | Description |
| Reference genomes | A catalog of sequenced genomes of microbes isolated from the human body. Early work reported 178 reference genomes in a 2010 Science paper and the project later reported roughly 800 human-associated reference genomes. Many have public accessions in NCBI databases with associated release dates. |
| 16S rRNA surveys | Targeted sequencing of the 16S ribosomal gene from thousands of samples from healthy adults across multiple body sites, showing which taxa are present and in what relative abundance. |
| Whole-metagenome shotgun data | Sequencing of whole-community DNA from samples across body sites. The healthy-human reference dataset is described by NIH as comprising over 2,000 metagenomes and more than 10 terabytes of sequence data. |
| Processed data and analyses | Assemblies, gene catalogs, taxonomic and functional profiles and metadata, hosted by the HMP Data Analysis and Coordination Center (DACC) and related resources. |
| Landmark publications | The June 2012 Nature papers, “Structure, function and diversity of the healthy human microbiome” and “A framework for human microbiome research,” plus numerous companion papers on topics such as the gut mycobiome and strain dynamics. |
| Later phases | The Integrative Human Microbiome Project and expanded datasets studying the microbiome in conditions such as inflammatory bowel disease, prediabetes and pregnancy and preterm birth, which add disease-associated signatures. |
| Controlled-access human data | Human host sequence data from subjects are held under controlled access through dbGaP and are not freely available to the public. |
Key point for prior-art analysis: The legal question turns on what was publicly accessible and as of what date. Open-access microbial data and publications are strong candidates for prior art. Controlled-access data are not obviously “publicly accessible” in the same way and require separate analysis.
The Legal Framework for Anticipation
Statutory basis
For U.S. patents governed by the America Invents Act, 35 U.S.C. § 102(a)(1) provides that a person is not entitled to a patent if the claimed invention was patented, described in a printed publication, in public use, on sale, or otherwise available to the public before the effective filing date. The grace-period exceptions in § 102(b)(1) cover certain inventor-originated disclosures within one year before filing. HMP publications and data releases are most naturally analyzed as “printed publications” and, for datasets, as materials “otherwise available to the public.”
Anticipation requires every element
A claim is anticipated only if a single prior art reference discloses each and every limitation, arranged as in the claim. Combining different references is the domain of obviousness under § 103, not anticipation. This single-reference rule is the main obstacle to using HMP data. A dataset may contain a vast amount of information, but anticipation requires the reference to disclose the specific combination claimed, not merely to contain the ingredients from which it could be assembled. A patent challenger must point to where the reference discloses the claimed arrangement, rather than relying on the possibility of selecting and combining elements.
Public accessibility
A reference qualifies as a printed publication when it was publicly accessible, meaning that interested persons exercising reasonable diligence could locate it. Case law, including In re Klopfenstein and later decisions, treats factors such as the length of display, the expertise of the intended audience, the existence of expectations of confidentiality and the ease of copying and indexing as relevant. For databases and online resources, evidence of the date of public availability and of how a skilled searcher would have found the data, is essential. Deposit dates and release dates in public repositories, archive snapshots and publication dates of associated papers can all serve as evidence.
Enablement of the prior art
Prior art references are presumed enabling and the burden rests on the patentee to show otherwise, but for anticipation the reference must still enable a skilled person to make or practice the claimed invention without undue experimentation. For product claims, that means the reference must put the claimed composition in the public’s possession. For a bacterial composition claim, one question is whether the reference makes the relevant strain obtainable: for example, through a deposit, a culture collection, or a reproducible isolation method. This is an area where HMP’s program of making reference strains available through culture collections can be significant, a point developed below.
Inherent anticipation
Inherency allows a reference to anticipate a claim when the claimed property or feature is necessarily present in what the reference discloses, even if the reference does not recognize it. The Federal Circuit has said that inherency cannot be established by probabilities or possibilities; the missing matter must necessarily be present. Cases such as Schering Corp. v. Geneva Pharmaceuticals and In re Cruciferous Sprout Litigation illustrate both the power and limits of the doctrine. In microbiome contexts, inherency could be relevant where an HMP-reported composition necessarily exhibits a property that a later patent claims as new, such as the presence of a particular strain at a particular abundance, or a functional capability encoded in the sequenced genome.
Where HMP Data Can Anticipate
A realistic assessment recognizes that HMP data are more likely to anticipate some types of claims than others.
| Claim type | Anticipation potential | Why |
| Claims to an isolated bacterial strain or its genome sequence, where the strain or sequence was released by HMP before the effective filing date | Potentially strong | HMP released reference genomes with accession numbers and made strains obtainable. A claim to the strain itself or to a sequence at a defined identity threshold may read on a disclosed reference genome. |
| Claims to a composition defined by the presence of specific taxa in a body-site sample, such as a naturally occurring community from a healthy subject | Potentially strong, but subject to eligibility and structure arguments | HMP 16S and metagenomic profiles disclose which taxa co-occur in healthy samples, which can match a claim that recites only the taxa. A challenger would need to show that the profile discloses the claimed taxa and any quantitative limits. |
| Claims to a diagnostic that identifies a taxon or gene as a biomarker of health | Moderate | If HMP data show the presence or abundance of the marker in healthy subjects, claims that only require detecting it may be anticipated, but claims requiring correlation with a disease state generally need more. |
| Claims to a composition defined by taxa and an intended therapeutic use | Depends on structural limits of the claim | An intended-use preamble often does not limit a composition claim unless it imparts structure or is essential to the claim. If the composition itself is disclosed, use limitations may not save the claim. |
| Claims to methods of treating a specific disease with a specific composition | Weak for anticipation | HMP’s healthy-cohort baseline data do not disclose administering a composition to a patient. These claims are better attacked through obviousness. |
| Claims to specific dosing regimens, formulations or manufacturing processes | Weak | Typically not disclosed in HMP data and need other prior art. |
| Claims to a consortium defined by a precise ratio, density or viability parameter | Weak to moderate | HMP relative-abundance data may show ratios, but anticipation requires the claimed ratio and arrangement to be disclosed clearly, not inferred. |
The Role of Strain Availability
For composition claims reciting live microorganisms, enablement of the prior art can turn on whether skilled persons could obtain the organism. HMP’s reference-genome effort involved isolating strains from human body sites and sequencing them and the project made many of those strains available through culture collections and repositories, with public sequence records for the genomes. A challenger should therefore gather evidence of:
- the public deposit or catalog listing of the specific strain and the date it became available;
- the strain’s accession number in sequence databases and the public release date;
- the culture collection’s distribution policy during the relevant period;
- any publication describing isolation and culture conditions sufficient to reproduce the strain.
Patentees often respond that a dataset describing which species are present does not provide the claimed strain-level composition, or that the claimed strains differ from the HMP isolates in sequence identity. The challenger’s answer will depend on a strain-by-strain comparison of the claimed sequences with the public records.
Obviousness: The More Common Use of HMP Data
In practice, HMP data are usually more potent as one reference in an obviousness combination under § 103 than as a sole anticipatory reference. The Supreme Court’s decision in KSR v. Teleflex directs a flexible analysis that considers whether a skilled person would have had reason to combine known elements with a reasonable expectation of success. In the microbiome context, a typical chain might be:
- HMP data show that a given taxon, such as a particular butyrate-producing Firmicutes species, is abundant in healthy gut samples.
- A disease-association study shows that the same taxon is depleted in patients with a specific condition.
- Prior probiotic or fecal-transplant literature shows that administering related bacteria to restore depleted taxa improves outcomes.
- A skilled person would therefore have had reason to administer the depleted taxon, with a reasonable expectation of success.
HMP data supply the first link: a baseline of what “healthy” looks like, which provides the motivation to replenish what is missing. Patentees often respond with arguments about unexpected results, lack of predictability in biology and the difficulty of culturing anaerobic organisms. The strength of the obviousness case therefore depends on specific evidence of expectation of success, not just on the existence of a baseline.
Eligibility and Its Interaction With Prior Art
Microbiome patents face a second, independent line of attack under 35 U.S.C. § 101. Under Funk Brothers (1948), Diamond v. Chakrabarty (1980) and Association for Molecular Pathology v. Myriad (2013), naturally occurring products are not eligible unless they have markedly different characteristics from their natural counterparts. Compositions consisting of naturally occurring bacteria in their natural state are vulnerable and the Federal Circuit has applied the natural-product doctrine in related contexts, as in Natural Alternatives International v. Creative Compounds. HMP data are relevant here too. They are strong evidence of what exists in nature, which helps a challenger show that a claimed composition is a product of nature and has no markedly different characteristics. The patentee’s response generally involves showing that the claimed composition differs in structure or function, for example through selection, formulation, purification, ratios or stabilization that do not occur in nature.
The two doctrines reinforce each other. If the claimed composition is the same as what occurs in healthy humans per the HMP data, the challenger can argue both that it is anticipated and that it is a natural product. If the patentee narrows the claim to avoid the prior art, for example by adding a specific formulation or ratio, the claim may move toward eligibility but also toward the realm where obviousness, rather than anticipation, is the governing issue.
Building the Evidentiary Record
Invalidity challenges succeed or fail on proof. For an HMP-based challenge, assemble the record carefully.
1. Establish dates
- Publication dates of the journal articles, including online-first dates.
- Public release dates of datasets in NCBI repositories, the DACC and related resources, with accession numbers.
- Archive captures (such as Internet Archive snapshots) of DACC pages and data directories, supported by declarations from custodians where needed.
- Culture collection catalog entries showing when strains became available.
2. Establish public accessibility
- Evidence that the data were open, indexed and searchable and that skilled persons in the field would have known where to look.
- Evidence of citation and use by third parties soon after release.
- Confirmation of which components were controlled-access (excluded or analyzed separately).
3. Map the claims to the disclosure
- Prepare a claim chart that matches each limitation to specific locations in the reference (figures, tables, accessions, supplementary data).
- For sequence-based limitations, perform alignments and report percent identity against the claimed sequences.
- For abundance or ratio limitations, extract the underlying numeric data and show the match.
- For functional limitations, identify gene annotations or published characterizations supporting inherency and explain why the feature is necessarily present.
4. Retain a technical expert
A microbiologist or bioinformatician can authenticate the data, explain how a skilled person would have used them and respond to arguments about strain variation, sampling bias or assay sensitivity. Their testimony also helps address the enablement question.
Forums and Procedures
| Forum | Notes for HMP-based challenges |
| Inter partes review (IPR) | Limited to patents and printed publications, which fits HMP papers and publicly released data that qualify as printed publications. Datasets and database entries need robust evidence of public accessibility. Grounds based on § 101 and § 112 are not available in IPR. |
| Post-grant review (PGR) | Available within nine months of grant for AIA patents. Allows eligibility, enablement and written-description grounds in addition to prior art, which suits microbiome patents well. |
| Ex parte reexamination | A lower-cost option based on patents and printed publications, with no estoppel, but with less participation for the requester. |
| District court litigation | Allows all invalidity grounds, including public use and on-sale bar, but requires clear and convincing evidence to overcome the presumption of validity. Expert testimony plays a central role. |
| Third-party submissions during prosecution | Pre-issuance submissions of HMP references can shape claim scope before a patent issues. |
| Foreign oppositions | The European Patent Office allows opposition within nine months after grant and the standard of novelty under Article 54 EPC is similar in spirit, requiring a direct and unambiguous disclosure. Eligibility is handled differently and exceptions for essentially biological processes and methods of treatment apply. |
Anticipated Counterarguments
| Patentee argument | Possible response |
| The HMP data show species, not the claimed strains | Compare sequences and accession records strain by strain. Show that the claim’s identity thresholds encompass the HMP isolates. |
| Controlled-access data were not public | Rely only on open-access datasets and papers and treat controlled-access data separately. |
| The reference is a dataset, not a disclosure of the claimed arrangement | Point to specific tables, figures and processed outputs where the combination is shown and avoid arguments that require selecting among many options. |
| The prior art is not enabling | Provide evidence of strain availability, culture protocols and routine methods. Prior art is presumed enabling, so the patentee must rebut. |
| The claimed composition has unexpected properties | Show that the properties are inherent in the disclosed composition or are not commensurate in scope with the claims. |
| Healthy-cohort data say nothing about therapeutic use | Argue the composition claim is limited by structure and not the intended use, or pursue obviousness with a disease-association reference. |
| The claims require a specific manufacturing process | Check whether the process limitations are product-by-process and whether the product is the same. Add manufacturing references if needed. |
Practical Guidance for Patent Drafters and Owners
The same analysis helps applicants who want their microbiome patents to survive. Drafters should:
- Review the HMP datasets and other public microbiome resources, during prior-art searches before filing and design claims around features not disclosed there.
- Claim at the strain or sequence-identity level that is actually novel and support it with deposits.
- Include functional, quantitative or structural limitations, such as defined ratios, viability thresholds, formulations or coating technologies, that distinguish the claim from natural communities.
- Prioritize method claims tied to specific patient populations, dosing regimens and clinical outcomes, with data supporting unexpected results.
- Disclose relevant HMP references to the Patent Office as part of the duty of candor.
- Prepare a fallback structure of dependent claims with progressively narrower, better-supported features.
Limitations and Open Questions
- Dataset-as-reference doctrine. Courts have decided fewer cases on whether large public datasets, as opposed to papers, qualify as printed publications. Evidence of indexing and accessibility is crucial.
- Selection from large disclosures. Challengers must show more than that the claimed combination could be assembled. Anticipation by a genus or large list can require that the claimed species be “at once envisaged.”
- Strain-level variation. Microbial genomes vary and identity thresholds in claims can produce disputes about whether an HMP isolate falls within the claim.
- Evolving law. Eligibility and obviousness standards continue to develop and the USPTO’s examination approach to natural products and microbiome claims has changed over time.
- Jurisdictional variation. Other offices apply different standards for novelty, inventive step and excluded subject matter.
Conclusion
The NIH Human Microbiome Project created a large, publicly available baseline of what the healthy human microbiome looks like. That baseline is a significant resource for challengers of microbiome patents, but it is not a universal weapon. Anticipation requires every limitation in a single reference, arranged as claimed and enabled, so HMP data are strongest against claims to strains, sequences or naturally occurring communities and weaker against claims to specific therapeutic methods, formulations and processes. For the latter, HMP data are best used as a foundational reference in obviousness combinations, alongside disease-association studies and clinical literature. Success depends on rigorous proof: dated, publicly accessible records, careful claim charts and credible expert support. For patent owners, the same lessons point toward drafting claims that go beyond what nature and the HMP, have already shown.
